Félix‑Ponce M, Jiménez‑Gracia AI, Laniado‑Laborín R

Language: Spanish
References: 11
Page: 363-365
PDF size: 220.89 Kb.

ABSTRACT

Introduction: Timely initiation of treatment is crucial for program management in countries with a high burden of multidrugresistant tuberculosis (MDR-TB). The delay in the initiation of the treatment allows the transmission in the community and the appearance of TB-MDR cases. Material and methods: Retrospective review of the files of the Tuberculosis Clinic of the Tijuana General Hospital, including all cases with a diagnosis of tuberculosis with rifampicin resistance (RRTB) or MDR-TB, during the period between 2006-2019. The interval (in days) between the regimen prescription and the start of treatment was determined. Results: 52 patients were included. The delay in the initiation of treatment after having recommended a treatment regimen for TB-RR /MDR was 115.6 ± 109.2 days (3.8 months) with a median of 97.5 days. The delay in patients who were cured was 113.4 days versus 155.0 days for patients who died (p = 0.83). Conclusions: The time interval between prescription of treatment of an RR/MDR-TB case and the start of treatment (115 days) is unacceptably long. The network for MDR-TB care would be strengthened with the decentralization of stocks of second-line anti-tuberculosis drugs.

REFERENCES

1. Htun YM, Khaing TMM, Yin Y, et al. Delay in diagnosis and treatment among adult multidrug resistant tuberculosis patients in Yangon Regional Tuberculosis Center, Myanmar: a cross-sectional study. BMC Health Serv Res 2018;18(1):878. doi: 10.1186/s12913-018-3715-4.

2. Harris RC, Grandjean L, Martin LJ, et al. The effect of early versus late treatment initiation after diagnosis on the outcomes of patients treated for multidrug-resistant tuberculosis: a systematic review. BMC Infect Dis 2016;16(1):193. doi:10.1186/s12879-016-1524-0.

3. Madala P, Jonnalagadda RK, Sastry TVSN, Samyukta R, Hanumanth N, Raju CN. A study to identify the factors responsible for the delay in treatment initiation of MDR–TB cases registered under RNTCP in a district of South India. Int J Scient Res 2016;5(9):397-401. doi : 10.36106/ijsr.

4. Pan American Health Organization. Tuberculosis in the Americas, 2018. Washington, DC: PAHO, 2018 Document Number: PAHO/ CDE/18-036.

5. Htun YM, Khaing TMM, Aung NM, et al. Delay in treatment initiation and treatment outcomes among adult patients with multidrug-resistant tuberculosis at Yangon Regional Tuberculosis Centre, Myanmar: A retrospective study. PLoS One 2018;13(12): e0209932. doi: 10.1371/ journal.pone.0209932.

6. Htun YM, Khaing TMM, Yin Y, et al. Delay in diagnosis and treatment among adult multidrug resistant tuberculosis patients in Yangon Regional Tuberculosis Center, Myanmar: a cross-sectional study. BMC Health Serv Res 2018;18(1):878. doi: 10.1186/s12913-018-3715-4.

7. Zhang X, Yin J, Li H, et al. Diagnostic and treatment delays of multidrug-resistant tuberculosis before initiating treatment: a crosssectional study. Trop Med Int Health 2015;20(11):1431-1437. doi: 10.1111/tmi.12566

8. Rifat M, Hall J, Oldmeadow C, Husain A, Milton AH. Health system delay in treatment of multidrug resistant tuberculosis patients in Bangladesh. BMC Infect Dis 2015;15:526. doi: 10.1186/s12879-015-1253-9.

9. Okethwangu D, Birungi D, Biribawa C, et al. Multidrug-resistant tuberculosis outbreak associated with poor treatment adherence and delayed treatment: Arua District, Uganda, 2013–2017. BMC Infectious Diseases 2019;19(1):387. doi: 10.1186/s12879-019-4014-3.

10. Rifat M, Rusen ID, Islam MA, et al. Why are tuberculosis patients not treated earlier? A study of informal health practitioners in Bangladesh. Int J Tuberc Lung Dis 2011;15(5):647–651. doi: 10.5588/ijtld.10.0205.

11. World Health Organization. Automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF assay for the diagnosis of pulmonary and extrapulmonary TB in adults and children. Policy update. World Health Organization 2013. ISBN: 978 92 4 150633 5.